Cite
HARVARD Citation
Donnez, J. et al. (2022). Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 400 (10356), pp. 896-907. [Online].